-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Reiterates Outperform on ACADIA Pharmaceuticals, Maintains $26 Price Target

Benzinga·05/19/2025 14:48:01
Listen to the news
RBC Capital analyst Gregory Renza reiterates ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Outperform and maintains $26 price target.